{"url_path":"/sec/avtx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1534120/0001534120-26-000033-index.html","accession_number":"0001534120-26-000033","cik":"0001534120","ticker":"AVTX","issuer_name":"Avalo Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1534120/0001534120-26-000033-index.html","primary_entity_key":"0001534120","primary_entity_name":"Avalo Therapeutics, Inc."},"word_count":382,"has_tables":true,"body_markdown":"Item 6.  Exhibits.\n\nExhibit\nNumberDescription of Exhibit\n\n4.1\n[Form of Pre-funded Warrant issued May](https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_ex4-1.htm)[7](https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_ex4-1.htm)[, 2026 by Avalo Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_ex4-1.htm)[(incorporated by reference to Exhibit](https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_ex4-1.htm)[4](https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_ex4-1.htm)[.](https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_ex4-1.htm)[1](https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_ex4-1.htm)[to the Current Report on Form 8-K filed on May](https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_ex4-1.htm)[7](https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_ex4-1.htm)[, 2026.](https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_ex4-1.htm)\n\n10.1**\n[Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization, effective upon April 26, 2026 (incorporated by reference to Exhibit 10.1](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000026/ex-101milestonebuyoutoptio.htm)[to the Current Report](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000026/ex-101milestonebuyoutoptio.htm)[on Form 8-K filed on April 28, 2026).](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000026/ex-101milestonebuyoutoptio.htm)\n\n31.1+\n[Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex-3111q2026.htm)\n\n31.2+\n[Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex-3121q2026.htm)\n\n32.1†\n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex-3211q2026.htm)\n\n101\nInteractive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025; (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the Three Months Ended March 31, 2026 and 2025; (iii) Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2026 and 2025; (iv) Condensed Consolidated Statements of Mezzanine and Stockholders’ Equity (Unaudited) for the Three Months Ended March 31, 2026 and 2025; and (v) Notes to Unaudited Financial Statements.\n\n104\nCover Page Interactive Data File, formatted in XBRL (included in Exhibit 101).\n\n+ Filed herewith.\n\n† This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n** Portions of this exhibit (indicated by asterisks) were omitted in accordance with the rules of the Securities and Exchange Commission\n\n36\n\n[Table of Contents](#ia91c2e9fd7f4434fb24288b227069962_7)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nAvalo Therapeutics, Inc.\n\n \n\nDate: May 13, 2026\n/s/ Christopher Sullivan\n\nChristopher Sullivan\n\nChief Financial Officer\n\n(on behalf of the registrant and as the registrant’s principal financial officer)\n\n37"}